| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5896996 | Cytokine | 2015 | 6 Pages |
Abstract
These results suggest that high mTOR activity contributes to TGF-β resistance and lowering mTORC1 kinase activity may provide a tool in high grade B-cell lymphoma therapy by restoring the sensitivity to normally available regulators such as TGF-β1.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Anna Sebestyén, Ágnes Márk, Melinda Hajdu, Noémi Nagy, Anna Molnár, Gyula VégsÅ, Gábor Barna, László Kopper,